In-Utero Sugar Restriction Cuts Offspring's Risk for Diabetes, Hypertension
By Lori Solomon HealthDay Reporter
THURSDAY, Nov. 7, 2024 -- Sugar restriction during the first 1,000 days after conception lowers a child's risk for later developing type 2 diabetes and hypertension, according to a study published online Oct. 31 in Science.
Tadeja Gracner, Ph.D., from the University of Southern California in Los Angeles, and colleagues examined the impact of sugar exposure within 1,000 days since conception on diabetes and hypertension. The analysis used a quasi-experimental design based on data from adults conceived just before and after the end of the United Kingdom sugar rationing in September 1953, which restricted sugar intake to levels within current dietary guidelines. Consumption nearly doubled immediately after rationing ended.
The researchers found that early-life rationing reduced diabetes and hypertension risk by about 35 and 20 percent, respectively. Similarly, rationing delayed disease onset by four and two years, respectively. With in-utero exposure restriction, protection was seen and increased with postnatal sugar restriction, especially after six months when solid foods likely began. One-third of the risk reduction was accounted for by in-utero sugar rationing.
"Parents need information about what works, and this study provides some of the first causal evidence that reducing added sugar early in life is a powerful step towards improving children's health over their lifetimes," coauthor Claire Boone, from McGill University in Montreal and the University of Chicago, said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Prenatal PFAS Exposure Linked to Elevated BP Through Adolescence
MONDAY, June 16, 2025 -- Prenatal exposure to specific perfluoroalkyl and polyfluoroalkyl substances (PFAS) is associated with offspring blood pressure (BP) through age 18 years...
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Increasing Proportion of U.S. Adults Unaware They Have Hypertension
MONDAY, June 9, 2025 -- From 2013 to 2023, there was an increase in the proportion of U.S. adults who were unaware of having hypertension, according to a research letter published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.